<SEC-DOCUMENT>0000879407-25-000027.txt : 20251125
<SEC-HEADER>0000879407-25-000027.hdr.sgml : 20251125
<ACCEPTANCE-DATETIME>20251125161059
ACCESSION NUMBER:		0000879407-25-000027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251125
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251125
DATE AS OF CHANGE:		20251125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		251521307

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>arwr-20251125.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:25a2e02f-75bf-448e-b7e1-c3fcd5f145f0,g:caa56abb-c661-4aeb-9c57-878b81f13af2,d:2fe6baea80524d998de505d590560e8a-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20251125</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20251125.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-25</xbrli:startDate><xbrli:endDate>2025-11-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2fe6baea80524d998de505d590560e8a_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:15pt;font-weight:700;line-height:115%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:15pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:15pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">PURSUANT TO SECTION 13 OR 15(D) OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 25, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">Date of Report </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(Date of earliest event reported)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:15pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Arrowhead Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38042</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">of incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 700</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices, including Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.054%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">ARWR</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2fe6baea80524d998de505d590560e8a_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 2.02 Results of Operations and Financial Condition </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On November&#160;25, 2025, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i2fe6baea80524d998de505d590560e8a_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01. Financial Statements and Exhibits. </span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(d) Exhibits </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:12.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-202511258kex991.htm">Press Release, dated November 25, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2fe6baea80524d998de505d590560e8a_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES </span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Date: November&#160;25, 2025</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.969%"><tr><td style="width:1.0%"/><td style="width:23.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.369%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Daniel Apel</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Daniel Apel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:115%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>arwr-202511258kex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ica6953583df147bfb1b6d1cfb864ad6e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 99.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div style="text-align:center"><img alt="ghvnqo5ppwcq000001a.jpg" src="ghvnqo5ppwcq000001a.jpg" style="height:67px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">PRESS RELEASE</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">November 25, 2025</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Conference Call and Webcast Today, November 25, 2025 at 4&#58;30 p.m. ET</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PASADENA, Calif., November 25, 2025</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Arrowhead Pharmaceuticals, Inc. (NASDAQ&#58; ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4&#58;30 p.m. ET to discuss the results.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), is a transformational milestone for Arrowhead. REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS and represents the first FDA-approval for a medicine leveraging Arrowhead&#8217;s proprietary and differentiated Targeted RNAi Molecule (TRiM</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">) platform,&#8221; said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. &#8220;However, Arrowhead is truly just getting started and we are well positioned to execute on our aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div id="ica6953583df147bfb1b6d1cfb864ad6e_10"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:150%">Webcast and Conference Call and Details</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investors may access a live audio webcast on the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Events and Presentations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For analysts who wish to participate in the conference call, please register at </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">https&#58;&#47;&#47;register-conf.media-server.com&#47;register&#47;BI2700430252ab408a89dff83808477869.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.</font></div><div id="ica6953583df147bfb1b6d1cfb864ad6e_4"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Selected Recent Events</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).<br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.11pt">FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis.<br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.11pt">This is Arrowhead&#8217;s first FDA-approved medicine, marking a major milestone for the company as it transitions into commercial-stage.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.11pt">REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS and can be self-administered at home with a simple subcutaneous injection once every three months.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.8pt">REDEMPLO is the first and only FDA-approved medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">The FDA approval is based on positive results from the Phase 3 PALISADE study where REDEMPLO significantly reduced triglycerides -80% from baseline and lowered the numerical incidence of acute pancreatitis compared to placebo.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Announced the One-REDEMPLO pricing model that creates one consistent price across current and potential future indications.<br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Launched Rely On REDEMPLO, a patient support program providing support services and resources for patients at each stage of the treatment journey with REDEMPLO, including financial assistance options for eligible patients.</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead&#8217;s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson&#8217;s Disease, and for other additional collaboration targets that will utilize Arrowhead&#8217;s proprietary Targeted RNAi Molecule (TRiM&#8482;) platform. Financial terms of the agreement include&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Arrowhead received a $200 million upfront payment from Novartis. Arrowhead is also eligible to receive development, regulatory, and sales milestone payments of up to $2 billion. Arrowhead is further eligible to receive tiered royalties on commercial sales up to the low double digits.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Filed a request for regulatory clearance to initiate a Phase 1&#47;2a clinical trial of ARO-DIMER-PA, the company&#8217;s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.8pt">ARO-DIMER-PA is a dual functional RNAi therapeutic designed to silence expression of the proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3) genes. This represents an important step forward for the RNAi field as it is the first clinical candidate to target two genes simultaneously in one molecule.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Filed a request for regulatory clearance to initiate a Phase 1&#47;2a clinical trial of ARO-MAPT, the company&#8217;s investigational RNAi therapeutic being developed as a potential treatment for tauopathies including Alzheimer&#8217;s disease, a progressive neurodegenerative disease characterized by cognitive and functional decline.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.8pt">ARO-MAPT is Arrowhead&#8217;s first investigational RNAi-based therapy to utilize a new proprietary delivery system which, in preclinical studies, has achieved blood-brain-barrier penetration and deep knockdown of target genes across the central nervous system (CNS), including deep brain regions, after subcutaneous injections.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Earned $300 million in milestone payments from Sarepta Therapeutics.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.8pt">$100 million milestone earned when Arrowhead reached the first of two pre-specified enrollment targets and subsequent authorization to dose escalate in a Phase 1&#47;2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">$200 million milestone earned following a drug safety committee review and subsequent authorization to dose escalate, and achievement of the second pre-specified patient enrollment target.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics to satisfy the payment of the first $100 million milestone owed to Arrowhead. The company believed this direct stock buyback of Arrowhead shares from Sarepta at $18.79 per share was an attractive option, given Arrowhead&#8217;s significant growth potential, both near- and longer-term. These shares were subsequently placed into treasury to reduce the number of Arrowhead shares outstanding.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company&#8217;s investigational RNAi therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran (licensed to Takeda) and olpasiran (licensed to Amgen).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead&#8217;s investigational cardiometabolic candidates in Greater China. Summary terms of the agreement include&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.8pt">Visirna will receive an upfront payment of $130 million from Sanofi. In addition, Visirna will be eligible to receive further milestone payments of up to $265 million upon approval of plozasiran across various indications in mainland China.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ica6953583df147bfb1b6d1cfb864ad6e_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Selected Fiscal 2025 Year-End Financial Results</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:115%">ARROWHEAD PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:115%">CONSOLIDATED CONDENSED FINANCIAL INFORMATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:57.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.370%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended September 30,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">OPERATING SUMMARY</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">829,448</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">3,551</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Operating Expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">607,159&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">505,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">123,943&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">98,761&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">731,102&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">604,631&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating income (loss)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">98,346&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(601,080)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total other expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(46,813)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(11,380)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Income (loss) before income tax expense and noncontrolling interest</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">51,533&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(612,460)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Income tax (benefit) expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,419&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(2,767)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Net income (loss) including noncontrolling interest</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30,114&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(609,693)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Net income (loss) attributable to noncontrolling interest, net of tax</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31,745&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(10,200)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(1,631)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(599,493)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ee2724;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ee2724;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5.00)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-average shares used in calculating - Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">133,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">119,784&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">September 30,</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">FINANCIAL POSITION SUMMARY</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">226,548&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">102,685&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Available-for-sale securities, at fair value</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">578,276&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value)</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">919,366</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">680,961</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other current and long-term assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">465,929&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">458,841&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total Assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">1,385,295</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">1,139,802</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Liability related to the sale of future royalties</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">367,397&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">341,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Credit Facility</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">254,883&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">393,183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,399&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">257,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">214,195&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">881,879</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">948,739</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">466,052</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">185,444</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling Interest</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">37,364</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,619</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total Noncontrolling Interest and Stockholders' Equity</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">503,416</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">191,063</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">1,385,295</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">1,139,802</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Shares Outstanding</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">135,702&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">124,376&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                                  </font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div id="ica6953583df147bfb1b6d1cfb864ad6e_76"></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">About REDEMPLO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> (plozasiran)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">REDEMPLO (plozasiran) is approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome (FCS). REDEMPLO is an siRNA therapeutic designed to suppress the production of apoC-III, a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting apoC-III with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is the first and only siRNA FDA-approved treatment studied in both genetically confirmed and clinically diagnosed patients living with FCS.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For more information about REDEMPLO, visit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Our Medicines</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">IMPORTANT SAFETY INFORMATION </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">CONTRAINDICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">None.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">ADVERSE REACTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Most common adverse reactions in REDEMPLO treated patients (incidence &#8805;10% of patients treated with REDEMPLO and &#62;5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Please see full </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Prescribing Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> for REDEMPLO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;.</font></div><div><font><br></font></div><div id="ica6953583df147bfb1b6d1cfb864ad6e_13"></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">About Arrowhead Pharmaceuticals</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing.</font></div><div style="margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For more information, please visit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.arrowheadpharma.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or follow us on X (formerly Twitter) at </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;ArrowheadPharma</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LinkedIn</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Facebook</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Instagram</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. To be added to the Company's email list and receive news directly, please visit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;ir.arrowheadpharma.com&#47;email-alerts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Safe Harbor Statement under the Private Securities Litigation Reform Act&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">This news release contains forward-looking statements within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;forecast&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts of REDEMPLO (plozasiran) on patient health and the health care system&#59; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates&#59; and our believes and expectations around the potential uses and value of the TRiM&#8482; platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Contacts&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Arrowhead Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Vince Anzalone, CFA</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">626-304-3400</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">ir&#64;arrowheadpharma.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Investors&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">LifeSci Advisors, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Brian Ritchie</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">212-915-2578</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">britchie&#64;lifesciadvisors.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">LifeSci Communications, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Kendy Guarinoni, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">724-910-9389</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">kg</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">uarinoni&#64;lifescicomms.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Source&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Arrowhead Pharmaceuticals, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"># # #</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>arwr-20251125.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:25a2e02f-75bf-448e-b7e1-c3fcd5f145f0,g:caa56abb-c661-4aeb-9c57-878b81f13af2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20251125" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20251125">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20251125_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20251125_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>arwr-20251125_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:25a2e02f-75bf-448e-b7e1-c3fcd5f145f0,g:caa56abb-c661-4aeb-9c57-878b81f13af2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_f0329b6c-58d4-4118-94f6-809c2a4caab4_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c0153b86-83f5-4171-b2fe-ce2e755cc9ea_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d3eeb960-9689-4854-8316-8fcf5312c0d0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a58414b2-191d-40c7-8f3c-5085362df336_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_65b43d18-6f8e-4dcf-83a8-f20444061550_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e49cca5c-f59f-44e2-8850-c1fd90588971_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7e7aaf8f-bffc-4b4b-8a84-65115270acff_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d71cf45d-5e7d-449e-b0f7-76a842461aeb_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_88a10173-2c18-4899-839a-c15361520521_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5ac4446c-041f-486f-ad2f-e320d8df58bf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_55a9ef70-4d00-4d1e-a05e-8bcf9ae8ceed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_37955d85-4534-4461-998d-ea78c2b06cce_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9388be37-5c8a-4d3e-a44e-e2a50a386ec9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2277fcee-3f7c-4967-903c-b3ac09dcefb2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_35a627b6-43f5-41f8-b774-3600cd71aeaa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_597e4fe2-8d7c-4c21-a7e6-2e97edd3f0b4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_45b75f46-aed3-4a43-92cd-d004d2bc3545_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_671e5a89-3664-44d1-b190-1b0af7e4dd71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_081067b2-cb45-4f69-aefc-43716fa6b4a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_57a039c1-bd5d-4ca0-9d98-6f5c9e144ae0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5eb7d807-9cec-4a7b-acb7-9a0ca9066cf7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_77634948-8d8c-4f74-b765-daa2ed8533f7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_73ad5f3a-1e0e-4770-b6d2-daa0a9e62a86_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>arwr-20251125_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:25a2e02f-75bf-448e-b7e1-c3fcd5f145f0,g:caa56abb-c661-4aeb-9c57-878b81f13af2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20251125.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3a12b086-6c81-4afb-b50c-d3c367094fd0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_DocumentType_3a12b086-6c81-4afb-b50c-d3c367094fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_66f0b24e-8a8e-481a-9fdb-47fbba301857" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_DocumentPeriodEndDate_66f0b24e-8a8e-481a-9fdb-47fbba301857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_42be1b73-bd78-4988-838d-4de3b8a1a343" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityRegistrantName_42be1b73-bd78-4988-838d-4de3b8a1a343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7e5c7bf0-ec66-4602-8cdf-cd02027b01c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7e5c7bf0-ec66-4602-8cdf-cd02027b01c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_515911ee-d1b4-4888-ae30-e87074b684c8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityFileNumber_515911ee-d1b4-4888-ae30-e87074b684c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ebb70746-79b1-4260-9afd-1a10fc3e7669" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityTaxIdentificationNumber_ebb70746-79b1-4260-9afd-1a10fc3e7669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6f7b85ca-d34e-4ac0-94e7-d0918a9ca294" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityAddressAddressLine1_6f7b85ca-d34e-4ac0-94e7-d0918a9ca294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6b514c51-20be-4b30-99f1-dd0492eac74f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityAddressAddressLine2_6b514c51-20be-4b30-99f1-dd0492eac74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e36c0280-1774-476d-9378-eae1d5416354" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityAddressCityOrTown_e36c0280-1774-476d-9378-eae1d5416354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4c3b82dd-10b2-46cb-a294-3d4dd252fce6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityAddressStateOrProvince_4c3b82dd-10b2-46cb-a294-3d4dd252fce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_51e7245e-82b5-4083-bdae-d7d93e2970d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityAddressPostalZipCode_51e7245e-82b5-4083-bdae-d7d93e2970d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_68f06c0e-5ee3-4a8c-bbe2-d0f988e86998" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_CityAreaCode_68f06c0e-5ee3-4a8c-bbe2-d0f988e86998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_263a1442-331c-42bd-9fe0-71f67a3b9b83" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_LocalPhoneNumber_263a1442-331c-42bd-9fe0-71f67a3b9b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7e7f7d71-3f57-4526-9d05-439e03c1b321" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_WrittenCommunications_7e7f7d71-3f57-4526-9d05-439e03c1b321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e91de1e0-d23f-4ef7-8b1e-84923714de80" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_SolicitingMaterial_e91de1e0-d23f-4ef7-8b1e-84923714de80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_030975df-f76b-4476-8282-f4c4a3d31b11" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_PreCommencementTenderOffer_030975df-f76b-4476-8282-f4c4a3d31b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3f292eab-2ed2-45f6-8c44-2a962e16813a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3f292eab-2ed2-45f6-8c44-2a962e16813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_263da5d9-a81c-41f1-b23e-c8446a0377f2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_Security12bTitle_263da5d9-a81c-41f1-b23e-c8446a0377f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ae6dfbed-ce4a-4c2d-871f-3fee51389cc3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_TradingSymbol_ae6dfbed-ce4a-4c2d-871f-3fee51389cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_112dfcb2-ea88-4bff-9ce3-7ed807dea331" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_SecurityExchangeName_112dfcb2-ea88-4bff-9ce3-7ed807dea331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e52effc2-5b95-46ef-9d1c-3f72fd883d42" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityEmergingGrowthCompany_e52effc2-5b95-46ef-9d1c-3f72fd883d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fb2ca979-febb-485e-ae58-5f2285940c08" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_EntityCentralIndexKey_fb2ca979-febb-485e-ae58-5f2285940c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e417692c-7886-4da5-bda4-1758534e5219" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861a754e-d9f8-4bdf-8944-c17ab97016a9" xlink:to="loc_dei_AmendmentFlag_e417692c-7886-4da5-bda4-1758534e5219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ghvnqo5ppwcq000001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ghvnqo5ppwcq000001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )8!P@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC8_KC%9TOQ+TE>(K6\<^I55'\Z\LHKHCEU%;W9B\94>QZ2WQ/M@?DTR4CWE
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X+/_Q\2?[Y_G4=23_\?$G^^?YU'69H>S>%
MO^17T_\ ZY#^=;%8_A;_ )%?3_\ KD/YUL5H9A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 4]6_Y U]_P!>\G_H)KPVO<M6_P"0-??]>\G_ *":\-J9%1"O
M=K'_ )!]M_UR7^0KPFO=K'_D'VW_ %R7^0HB$BQ1115$A1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!9_
M^/B3_?/\ZCJ2?_CXD_WS_.HZS-#V;PM_R*^G_P#7(?SK8K'\+?\ (KZ?_P!<
MA_.MBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO7&W\E'^->85ZW\.XO+\+!L?ZR=V_D/Z5PY@[4?F=6#5ZIUE%%%>">L%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >"S_\
M?$G^^?YU'4D__'Q)_OG^=1UF:'LWA;_D5]/_ .N0_G6Q6/X6_P"17T__ *Y#
M^=;%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8="IP170Z7XUU?3F59)OM<(ZI-R?P;K_ #HN'*>MT5C:'XEL-=CQ"QCN ,M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\
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MHHHJB3 \;?\ (H7W_;/_ -&+7D%>O^-O^10OO^V?_HQ:\@J64BYI/_(9L?\
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M[5T.UNB<N4VR?[PX/^/XUIU9 4444 %%%% !7DOC?4OM_B*2-6S%:CRE^O\
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M)&.5'^TO;]17/4AGIOA/QA_:16PU!@MWC$<O02^W^]_.N1\;?\C???\ ;/\
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MJ("BBB@ HHHH *X;Q7X+29'O]*BVS#F2!1P_NH]?;O\ S[FB@$SP&BNS\>:
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M+&#] 2?YBN\JEL2]PHHHIB"BBB@ HHHH **** "O*/'6G"Q\0M,@Q'=+YO\
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M_P"%EP_] Q_^_P /\*+H+,[NBN$_X67#_P! Q_\ O\/\*/\ A9</_0,?_O\
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M0?;?]<E_D*\)KW:Q_P"0?;?]<E_D*(A(L44451(4444 %%%% !1110 4444
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M_-(SM]2<UT9;3O-S[&.-G:*CW(:***]H\P**** "BBB@ HHHH *U_#%G]O\
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MF(**** "BBB@ HHHH *Y/XA?\BVO_7PO\FKK*XKXD3A=*L[?/,DY?_OE2/\
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M_P#?D_XT6871PE%=W_PK2;_H)Q_]^3_C1_PK2;_H)Q_]^3_C19A='"45W?\
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M_P A7A->[6/_ "#[;_KDO\A1$)%BBBBJ)"BBB@ HHHH **** "BBB@ HHHH
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M5_M+Q%)&C9AM1Y*_4?>/Y\?A7,U]#@J7LZ*ON]3Q\34YZC\@HHHKK.<****
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M1>TW_KTB_P#0!3B*1H44451)@>-O^10OO^V?_HQ:\@KU_P ;?\BA??\ ;/\
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MQ_Y!]M_UR7^0IQ%(L44451(4444 %%%% !1110 4444 %%%% !1110 4444
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M.IS'$?)3Z+P?US6#7KX2G[.BD>=B)\]1L^AZ*CM_^/:+_<'\JDKYP]H****
M"BBB@ HHHH **** "BBB@#F_&>BG5M&,D*YN;;,B =6'\0_K^%>2U[]7E_C3
MPT=.N6U"TC_T.5LNJC_5,?Z'_P"MZ5+129R->C>#O%J3QQZ9J,@691MAE8\.
M.RGW_G]>OG-%),;1[]17E^@^.KK3U6WOU:ZMQP'S^\4?U_'\Z[W3O$&EZJH^
MRWD9<_\ +-CM?\C_ $JDR6C3HHHIB"BCIS6-J7BG2-,4^;=I)(/^64)WM^G
M_'% &S7G_C/Q:DD<FEZ=)N!^6>93P1_=']3^%9.O>-;W5E>WMP;6U;@A3\[C
MW/\ 0?K7+U+92045:T^PGU.]2UMUR[<D]E ZD^U5:105[=H7_(O:;_UZ1?\
MH KQ&O;M"_Y%[3?^O2+_ - %.),C0HHHJB3 \;?\BA??]L__ $8M>05Z_P"-
MO^10OO\ MG_Z,6O(*EE(N:3_ ,AFQ_Z^(_\ T(5[E7AND_\ (9L?^OB/_P!"
M%>Y41"044451(4444 %%%% !7EGQ"_Y&1?\ KW7^;5ZG7EGQ"_Y&1?\ KW7^
M;4F..YRE=_\ #/\ YBG_ &R_]GK@*[_X9_\ ,4_[9?\ L]2MRGL=_1115D!1
M110 4444 %>/^+-$.C:RXC7%K/F2$]AZK^!_3%>P5F:[HT.N::]K+A7'S128
M^XW^'K2:N-.QXI6KH&N3Z#J N(LM$WRRQ9X=?\1V-4;VRGT^\DM;F,I-&<,/
M\]J@J2CW/3M2M=5LUNK24/&W7U4^A'8U;KP_2]7O='N?/LYBA/WE/*N/0BO0
M])\?:=>*L=\#:3=R>4/X]OQ_.J3):.MHJ.&>*XC$D$J2QGHR,&!_$5)3$%%%
M,EFB@C,DTB1QCJSL !^)H ?5:^O[;3;1[J[E$<2=2>Y]!ZFN=U;QYIMBK)9_
MZ9/T&WA!]6[_ (5YYJVM7VM7/G7DN['W$7A4^@I-C2+'B+7Y]>O_ #6!2W3B
M&+/W1ZGW-8]%36MK->W4=M;QF261MJJ*DLU/#&BMK6LQQ,I-O&=\Q[;1V_'I
M^=>Q@   # '05E>'M#BT+3%MUPTS?--)_>;_  ':M:J2(;N%%%%,04444 <#
M\1]-RMKJ:#I^YD_FI_G^E>?U[AK.GKJFD75D<9E0[2>S#D'\P*\0961V1P59
M3@@]C4LI%[3M6GTVWOHH?NW</E-STYZ_ED?C5"BBD436EM)>WD-K$,R2N$7\
M37N5K;QVEI#;1#$<2!%^@&*\W^'NF_:=8DO77,=JGR_[[<#],_I7IU4B9!11
M13)"BBB@ KRSQ]IOV/7!=(N([M=WMO'!_H?QKU.N=\:Z;_:'AV5T7,ML?.7Z
M#[P_+)_"DQK<\CK0CU:>/0IM*'^IEF64G/H.1^)VG\*SZ*DL*U?#>F_VKKUK
M;,,Q[M\G^Z.3^?3\:RJ]$^'.F[+:YU)Q\TA\J,_[(Y/YG'Y4(3.ZHHHJR HH
MHH **** /!9_^/B3_?/\ZCJ2?_CXD_WS_.HZS-#V;PM_R*^G_P#7(?SK8K'\
M+?\ (KZ?_P!<A_.MBM#,**** "BBB@ HHHH YCQ]_P BN_\ UU3^=>45ZOX^
M_P"17?\ ZZI_.O**E[E+8U/#G_(R:;_U\)_.O:J\5\.?\C)IO_7PG\Z]JIQ"
M04444R3R7QIHQTO6FFC3%M=$R)CH&_B'Y\_C7-U[9KFCPZWIDEI+@-]Z-_[C
M=C7C5[93Z?>26MRA26,X8?U'M4M%IE_P_KDV@ZBLZ9:%_EFC_O+_ (CM7K]C
M?VVI6B75I*)(G'!'8^A]#7A5:.CZY?:)<^;:284_?C;E7^H_K0F#5SVVBN8T
MGQSI>H*J7+_8YSP5D/R'Z-T_/%=*CI(@>-E=3R&4Y!JB!U%%% !14%S>6UE%
MYMU/'"@_BD8"N/UGX@V\*M%I2>=)T\YQA!]!U/Z?C1<+&]XA\0VV@V1=RKW+
MC]U#GECZGVKR"[NIKZ[ENKAR\TK;F8T75W<7UR]Q=2M+,YRS,:AJ&[EI6"O1
MOAYIL\=K-J$KR".3Y(8]QVD \MCIUX_ UR/AS09M=U%8@"MNGS32#L/0>YKV
M*"&.V@C@A0)'&H55'0 4TA-DE%%%4207EI%?64UK.,QRH5;\:\2U*PFTS4)K
M.<?/$V,_WAV(]B.:]TKEO&7ALZQ:"[M4S>P+T'_+1?3Z^E)H:9Y571^%/$SZ
M%<F&?<]C*?G4=4/]X?UKG2""01@CJ*2I*/>H)XKF!)H)%DB<95U.014E>,Z'
MXDO]"DQ ^^!CEH7^Z?<>AKT/2_&FD:BJK)-]DF/5)C@?@W3^54F2T='12*RN
MH96#*>A!R#2TQ!115.]U:PTU2UY=Q0X_A9OF/T'4T 7*P?$GB6WT*U*@K)>.
M/W<6>G^TWM_.N=UGXA;E:'28B,\?:)1S^"_X_E7"332W$SS32-)(YRSL<DFD
MV4D+<7$MW<27$[EY9&+,Q[FHZ "3@<DU8O;*;3[IK:X7;*JJS+Z;E#8^O-24
M5Z]'^&W_ "#[[_KJO\J\XKT?X;?\@^^_ZZK_ "H6XGL=O1115D'*>.]%.HZ2
M+R%<SVF6('5D/7\NOYUY97OW6O*/&'AIM'O3=6R'[#,V5P/]6W]WZ>G_ -:I
M:*3.8Z'(KT[PAXM34(DT^_D"WBC".Q_UH_\ BOYUYC2@D$$'!'0TDQM7/?:*
M\TT+Q]<6BK;ZFK7$(X$J_P"L'U_O?S^M=UI^N:9JB@VEY&['^ G#C\#S57):
M-&BBBF(**0D $DX ZFL34O%NCZ:I#W2S2#_EG!\Y_P !^)H VR0!DG %><>,
MO%JW@;3-.DS!G$TRG[_^R/;W[_3KF:]XQOM95H$_T:T/6-#RW^\?Z5SE2V4D
M%%6K&PGU"9XX%SY<;2.W9549)_SZU5I%!7NUC_R#[;_KDO\ (5X37NUC_P @
M^V_ZY+_(4XDR+%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!Y-\1;7R/$PF XN(5;/N/E_D!7(UZ;\3++S--L[U1S#
M*8V^C#_%?UKS*OHL'/FHQ\M#QL3'EJL****ZC **** "BBB@ HHHH *]+^'&
MLB:SETF5OGAS)%D]5)Y'X'^=>:5;TS4)M*U*"]MS^\B;..S#N#[$<5AB:/M:
M;B:T:GLYJ1[Y1533=0@U73X;VW;,<JY [@]P?<&K=?-M-.S/:335T%(0&4@@
M$$8(-+12&><^)_!4D#O>Z5&7A/+VZCE/]WU'MV_EQ/2O?*Q-7\*Z7K!:26$Q
M7!_Y;1<$_7L?QKDJX:^L#@KX)2?-3/'J*[*\^'5_$Q-G=0SIV#Y1OZC]:RW\
M&:^A_P"/ L/59$/]:Y'1J+H<,J%6.\68-%=%#X(UZ4C=:I$#W>5?Z$FMS3_A
MS\P;4;T8[QP#K_P(_P"%.-&H^@XX:K+9'$6EI<7UPMO:PM+*W15'^>*]/\+^
M%(M%3[3<[9;YAU'2,>@]_?\ R=G3M*L=*A\JRMUB!^\1RS?4]35VNREAU#5[
MGH4,(J;YI:L****Z3L"BBJFHZA;Z582WET^V*,9/J3V ]S32;=D)M)79C>,?
M$(T32BD+_P"F7 *Q =5'=OP[>]>.=3DUH:SJUQK6IRWMP>6X1,\(O8"L^OH<
M+AU1A;J]SQ\16]I*_0****ZC **** "BBB@ HHHH *GL[62]O8;6$9DF<(OU
M)Q4%=M\.-*^TZK+J,B_N[5=J9[NW^ S^8K*M45.FY]C2E#GFHGI5I:QV5G#:
MQ#$<*!%^@&*K:WJ TK1;N]) :.,[,]V/"_J16A7G_P 2]3VP6NF(W+GSI #V
M'"_KG\J^?P]-U:JBSUZT_9TVSSDDL2222>23WI***^D/$/?[#G3K4G_GDG\A
M5BJ6DDG1K$DY)MXR2?\ =%7:^6E\3/?CL@HHHJ1A1110 4444 %%%% !1110
M 5'-#%<0O#,BR1N-K*PR"*DHH \L\3^#I]*9[JR5IK'J1U:+Z^H]_P ZY2O?
MJY36_ MCJ+-/9D6EP>2%&48_3M^'Y5+129Y916OJ7AG5M++&>T=HQ_RUB&Y?
MS'3\<5D4AEV#6-2M1B#4+J-?[JRL!^6:LGQ/K94*=3N<#T?!K)HH LW&HWUV
M,7-Y<3#TDE+?SJM13XH99Y!'#&\DAZ*BDD_@*!C*L65C<ZC=);6D32ROT4?S
M/H*Z72? .HWC+)?$6D/<'ES^';\?RKT+2M&L=&M_)LX0N?O.>6?ZFFD)LSM"
M\.0:!I<HR)+N1#YLOX=![?SKR&O>I_\ CWE_W#_*O!:&)!7MVA?\B]IO_7I%
M_P"@"O$:]NT+_D7M-_Z](O\ T 41"1H44451)@>-O^10OO\ MG_Z,6O(*]?\
M;?\ (H7W_;/_ -&+7D%2RD7-)_Y#-C_U\1_^A"O<J\-TG_D,V/\ U\1_^A"O
M<J(A(****HD**** "BBB@ KRSXA?\C(O_7NO\VKU.O+/B%_R,B_]>Z_S:DQQ
MW.4KO_AG_P Q3_ME_P"SUP%=_P##/_F*?]LO_9ZE;E/8[^BBBK("BBB@ HHH
MH **** ,3Q%X;MM?MOFQ'=(/W<P'Z'U%>4:EI=YI%T;>\B*/_"?X6'J#W%>Y
M55OM/M-2MC;WD"2QGLW4>X/4&DT-.QX717<:O\/+B(M+I4PF3KY,I 8?0]#^
M.*Y"\T^\T^3R[NVEA;MO4C/T/>IL410W$]L^^":2)O[T;%3^E:<7BC7(@ NI
MW!Q_?;=_.LBB@9KR>*=<ESNU.<9_NG;_ "K-GNKBZ??<3RS-_>D<L?UJ*B@
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MR0R##*W>IJ* /)O$OA&XT61KBW#36)/#]3'[-_C7-5[Z0&!! (/!![UR&M>
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MMO\ KDO\A7A->[6/_(/MO^N2_P A1$)%BBBBJ)"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$.G_VIX?O;0#+O&2@_P!H
M<C]0*\+KZ'KQ3Q;IG]E>([J(+B*1O.C_ -UN?T.1^%>KEE35TWZG!CH;3,.B
MBBO7/."BBB@ HHHH **** "BBB@#IO!_B=M"O##<$FPF/S@<[&_O#^O_ -:O
M7TD26-9(V#HPRK*<@CU%?/5=9X3\8RZ*RV=YNEL&/&.6B/J/;U'Y>_FXW!^T
M]^&_YG;AL3R>Y+8];HJ&VNH+RW2XMI5EA<95U.0:FKQ6K:,],**** "BBB@
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M"BBB@ HHHH **** "BBB@ HHHH **** "J%WHFEWQ)N;""1CU;8 WYCFK]%
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M5)THHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU9;18.M36\D=;3)98X(FDFD2.-1EF=L ?C7FM_\ $N]E!6PLXH!_?D.]ORX
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M@TD^$M/).?D/_H1K=KY>M_$EZL]VG\"] HHHK,L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M("OC/!QVKQ"O6_ O_(J6W^^__H1J4RFCHZ***HD**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K.UK2(-;TR2RGXW<H^.4;L16C13C)Q=T)I-69X%J%A<:9?2V=TFR6-L'T/
MH1[&JM>Q>+_#"Z]9>;  M]"/W9Z;Q_=/]*\?DC>*1HY%*NA*LI&"".U?18;$
M*M"_7J>/7HNE*W0;111728!1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWD&Z%SU(]#[C_"IO!NI-IWB*W&[$5P?)<?7H?SQ^M"T&]3U^N0^(W_(O6_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\5ZY-$\4FH.R.I5@47D'KVKTW_A%M#_Z!D'Y&H[CP[X=M;>2>>PMHXHUW,S
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M[C_^@FM#XD?\AFT_Z]__ &8UG^!?^1KMO]Q__034]2^AZW7E7Q =F\3$$\+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC7A->\W,9FM9HE(#.C*,].17FO\ PKG6/^?FQ_[[?_XFDQH[#P3_ ,BA8_\
M;3_T8U;]9?AW39M)T*VL;AHVEBW;C&25Y8GN!ZUJ52)84444 >,^*?\ D:-0
M_P"NI_E73_#/_F*?]LO_ &>DUKP-J>HZS=7D,]HL<K[E#NP(^N%K9\(>'+SP
M_P#;/M<L#^?LV^4Q.-N[.<@>M2EJ4WH=/1115$GB.N_\C#J7_7W+_P"AFNW^
M&W_(/OO^NJ_RJCJ7@+5;S5;RZCN+,)-.\BAG;(!8D9^7WKHO".@76@6MS%=2
M0NTKAE\IB1T]P*E+4IO0Z.BBBJ)/";[_ )"%S_UU;^9KT?X<_P#(O7'_ %]M
M_P"@)6)<_#W5IKJ:5;BR"N[,,N^>3_NUUGA/1;G0M*EM;IXG=YS(#$21@JH[
M@>E2EJ4WH;U<%X]\//(W]L6J%L+BX51S@=&_+@_A[UWM(0",$9!JB4SP-6*,
M&4D,#D$'D5U>G>/]4LXA%<I'=J!PS_*_XD=?RKH=:\ VE[(T^GR"UE8Y,9&8
MR?;NO^>*Y6;P+K\3[4M8YA_>290/_'B#4V:+NF:%U\1K^6(K;6D,#'^-B7(^
MG05R5Q<W%]<O/<2/-,_+,W)__570VO@+7)WQ-'%;+W,D@/\ Z#FNNLO!=KIV
MEWD43":^GMWB$\HP%+*1P.<#GW-%FQ72/*J]F\+?\BOI_P#UR'\ZXC_A7.L?
M\_-C_P!]O_\ $UZ!HME)IVC6MG,R-)$FUBA)!^F:$@;+]>9^-_#<EI>2:I:Q
MYMICF4*/]6YZGZ'^?X5Z93719$9'4,C##*PR"*;0D['A%M<S6EPD]O*T4J'*
MNIP177V7Q'OH8PMW9Q7!'\:MY9/UX(_(5J:O\/;:X=I=,F^SN>?*?E/P/4?K
M7-2^!=?C?:EJDH_O),N/U(I:HK1ES4/B%J-U$T=I#':!OX@=[CZ$\?I6+I'B
M"_T>\:XAE9Q(V98Y"2)/K[^]:$'@37IGVR010#^])*I'_CN:ZS1/ EEISK<7
MK_:YUY"D813]._X_E1J+0Z+3;W^T=.@N_(DA\U=VR3J*H>)]#&N:0T*8%Q&=
M\+'U]/H?\*VJ*HD\$FAEMYWAF1HY4.&5A@@UUVC^/[NRA6"^A^U(HP) V' ]
M_6NRUSPM8:Z-\H,5R!@31CG\1W%</>?#_6(&/V<PW*]BK[3^3?XU-FBKIF\_
MQ(L A,=C<LW8,5 _/FN2UWQ5?Z[^[DQ#; Y$*'@_4]ZE7P1XA+ &Q"CU,R?X
MUL:;\.9V=7U*Z2-.\</+'\3P/UHU#1&)X2L=0O=9064TL"(0TTJ$@!?3W)]*
M]@JK8:?:Z9:K;6<*Q1#G ZD^I/<U:II";N5[ZU2^L9[23[LT90GTR.M>'W=K
M-97<MM.A26)BK#WKWBN?\1>%+37AYH;R+M1@2@9##T8=Z&@3/.M"\37V@LRP
M%9('.6ADZ9]1Z&MZ;XDWC1D0V$,;]F9RP'X<5FW'@/787VQP13K_ 'HY5'_H
M6*=:> M;GDQ-'%;+W9Y WZ+FEJ5H85]?7>J74EU=2/-)CECT49_0<_K56O47
M\%0V_ANZL+)D:\N @:>;@'#!L<9P.*YW_A7.L?\ /S8_]]O_ /$TK,+H]'L?
M^0?;?]<E_D*L5%;1F&UAB8@LB*IQTX%2U9!P'Q,_YA?_ &U_]DKF/"W_ "-&
MG_\ 74?RKO\ Q?X<O/$'V/[)+ GD;]WFL1G=MQC /I6-HO@;4].UFUO)I[1H
MXGW,$=B3],K4M:E)Z'H%%%%42>:?$C_D,VG_ %[_ /LQK/\  O\ R-=M_N/_
M .@FNL\6^%;[7K^">UEMT6.+81*S YR3V!]:J^&_!NHZ/K<-[<36K1HK B-F
M)Y!'=14]2KZ'<UEZ_H\>MZ3):,0LGWHG/\+#I_A^-:E%42>$7EG<6%U);7,9
MCFC.&4_YZ5J:-XJU+1%$4+K+;Y_U,HR!].XKT[6?#]AKD06ZC(D4829.&7_$
M>QKAK[X>:G"Y-G-#<Q]LG8WY'C]:FS15TRVWQ+F\K"Z8@D_O&8D?EC^M<SJ_
MB'4=:F5[J;"H<I''\JJ?4>_N:MCP3XAS_P @_'_;:/\ ^*K5T[X=7LKJVH7$
M<$?=8_F?_ ?K1J/0TO!?BB\U"8:;=QO.RKE;@=0!_?\ \:[>J.EZ39:/:_9[
M.((IY9CRSGU)J]5(EGE'C+P\^E:BUW"A^QW#9!'\#'JO]1_]:N=M;J>RN$N+
M:5HID.5=3@BO=9X(KJ!X)XUDB<89&&017"ZK\.MSM)I5RJ@\B&;.!]&_Q'XU
M+0TRE:_$:_BB"W-I#.P_C4E"?KU%0:A\0-4NXVCMHX[16ZLF6?\ ,]/RJH_@
M?Q K$"R5QZK,F#^9JY8_#W59W'VMXK6/O\V]OR''ZT:CT.4.^0NYW,?O,QY_
M$TVO4[WP;$OAU].TSRUF=U=YIR<OCU('Z8KF_P#A7.L?\_-C_P!]O_\ $TK!
M='I]1S_\>\O^X?Y5)3)5+Q.HZLI JR#P2O6_ O\ R*EM_OO_ .A&N3_X5SK'
M_/S8_P#?;_\ Q-=SX;TN?1]$BLKAHVD1F),9)'))[@5*139J.BR1LC#*L""/
M:O#]5TZ;2M2GLY@=T;8!_O+V/XBO<JR-<\/66O0*MP"DR#Y)D^\OM[CVIM7$
MG8X;PUXU;2+5;*\A>:W0_(R$;D'I@]16_/\ $;2TBS!;74DF.%8!1^)R?Y5S
MM[\/]8@<_9O*ND[%7"'\0W^-54\#^(&;!LE0>K3)C]#2U'H96J:E-JVHS7L^
M \AZ+T ' 'Y5W_PZL)+?3+F\D!47+@(#W"YY_,G\JJZ3\.PDBRZK<*X!SY,.
M<'ZL?Z#\:[N.-(HUCC4(B@*JJ,  =J$@;'44451(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQAL8SM &?TJQ12L.X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 25,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arrowhead Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="arwr-20251125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="arwr-20251125.htm">arwr-20251125.htm</File>
    <File>arwr-20251125.xsd</File>
    <File>arwr-20251125_lab.xml</File>
    <File>arwr-20251125_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arwr-20251125.htm": {
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20251125",
   "dts": {
    "inline": {
     "local": [
      "arwr-20251125.htm"
     ]
    },
    "schema": {
     "local": [
      "arwr-20251125.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20251125_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20251125_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20251125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20251125.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000879407-25-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000879407-25-000027-xbrl.zip
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M(D&]$&E!(Z N#*H7%*VLY/5TG$E?N,OSXYL4@GQN=5Z;S5O+ENFD\"&'Y%T
M</.PCT%G:(IF*+J1#@(M[Q\!#C_W:9@"MXF,>J52R4V0W#.,UP9=:HI?YSAL
MFUS/+^ AFU=="OR:89[RI9NI70X8M6N70Q91@B,H[.\1?[C*-'PO MY5>M,
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MA!XHV_DMU'YFCG]WT_E,=G<94N\_=J!BQP#,0UGYN.X5O##=R3&=U",GH*A
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M <4V41:Q$NDR,/?R'']>BZ%021U&#F:5.X&LF 2Q810T$+@(SDAX/!Q 9W"
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M!R19Z<399.TZ,E",=#747= 3*SD"O.9HZR&1/=EBWV:_@'SIFGED\7IFA!O
M;H+<4@@U6N@7@/#@ <)K&E$BSXW+P,J2K3"#0R)Z%^(Q,8)<:MO)WP.0 2,.
M@3,0^7<#[.1^OG-UA]V0GS;3A><"CY?J>HXZPATCH&[K?;O>^])Y[,+G4PQO
M;A>2PW'N^N\1%TG8MFLB8D/2VQY!V&W1$2:J92P=WS>(T_0A*(*EFJ>[^FQ
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MBG,86)=K@1?8^W3S[.*NB.D#%H*8B!F+X&T?,LVERXX&D03DA -P .W@&_<
M1!9XL.(Q^-@KF&% :V 0<W1RB9YA"EVIH?RNACBWUI0+1+A%"2 ,C9C!W)$/
MTC"_9"IPM:%@/!+P SQ1IDOX"NQ%?(79C04@E*D$(-3O@Q@:-,SZ"H,[F YZ
M(L!L!.[+@;&BJID+,G@JQ+S/8EW,'.&LV4_QOH[R?1&1D\5[!;P+0/+!$B4B
M/50Q@<YC :C<XV#+ P$>'.CS &U=A.AX@]@S,"6+"&%0@8C@*!2)K %N@N-%
M3ZU3=3^;HUPQ=2T]PN\W$<IK&# SWD*0FL-KCL$+2$\_@9UM(F 0!S@+[M#]
M1IKY&,\=!Y''T6T"R!-7*H"Y&31@&O&Q$:YB5.4*1T44-SXF .7(^*63._+D
MJ/\KX];I$+TI4A7ROF D'^EKHF M'!0,@S!^,?$XH&%P(J+(VAB:/)B'])!,
M]4,) .O"A-P!O,CJ*5)]E1!%!=AS/%1 EA*X!^_%8SL.' ]<R>2&R)RVDO2<
M8K0&+C'2R$D& %FI!^@BT;U!! ]!2^AZ4[5,,TD+8HN $ >*[T,P =U!F-A(
MG%L&\4$<AYI8[8\?J@WS3R9P 4=41*K""W!C<.-%<.$SA] ?OYV5P:E5*\"2
MR[Q;+35YL^7V>LU*L]2L-AK->JNXH?C.+G$V,F&%:[&12@SFD<.B)\*9@P%Z
M!9C%("'*C_;.@>5%&FDDW [,_^P"YM?%P_G$:"+Q5R(C$Y]3_[;$&E8+4=6Y
MU=69:A8Z^"E_3R6Y/*2C'0$,E/BHR0^,^UPU9(7<=8$>%#S1BS]6Y@<Q\Y$D
MLO&Q8#?#-4J;[0AF&<8&24+AT:KFDA2H?K@9(Y[1CUTITN#;XRR9@(GH^Z/8
M*;)3I0RA/(X2R"Q<(%Y@ L;\(6DZ;A^P :9F698SSHCV0T]]XUI"+@5Y%61:
M/C(0B04><&Y(WS =VJ>LZ&"<QEBODN<5EX:+&?TTYMO$B^''7A$_K4:IG O\
M5(LH,P0X2%PI>]:8K,!$1IA_0":!H<LRTP,3"SR#&('+ZE:M5,I2X#3R$>2F
MT^&^" 2$1P;1<YR)P)T@+QGPB(./B,BK=D<SN*!DV-,&R@[<%5RL74(0V7#+
MF-0P@ $1#8&O \SU/3B+X\#("3.=="&?HF0%V$MZ-"1SMTA5TK2'"C^83%D8
M!9(H&J=!XT0'SNWQ&"X>\H"6W2 3TSO\/3_^;@: /OC_P^+'_=H)X&7B;B!V
MW)KZG<^_ ,IF2SUILDG%/G!,,C:U(<JFT?D 4B8);P'PTA>+V>LJ<6DE/KL#
MR%, \G*UNM3#:.'U"CR-D$@2D:</,.@8YP=7]?$2X%G 9_! J 0Q]"5+N9!A
MHN\$7S:(A& ^C'.PI 3\9O!T!&F?!.\)$_N3!:-2.N2.> IKR@VH2H8UK8.I
M,9K :2!:X@28C8N1#W(_2?6!Z9!'H0/S)AGY:4TOBX#P!20:?= C? $@W *(
M/-_:0FX@4BU6ZR8PB=D%#L *5JP1(VEI]DY,5J2 I1*4K@:8\E?85?O\#!?G
M"# C!J$-:-48=QKT+WL "JJ9&HKLWN/(A6;I;^:Z6:&<T.2I(3DIO!GDJW P
MDBL9.%B2!E<$-(>XS0QS,=$PS51##\RXJQ;#;[J/YV%!_WYG3W96FIR6)J?P
MKE8>B+)N,Y#Y=Q!-4-P7A2Z,Y;9 1:B/W!ORD9Z]_?,U(+V,]>TRVO4S6L$N
MX92QU801>N(^1%A7>&F60"UQFB'S Z^K,83#$/!(,!?((S5@WS#\68+/>DF<
M1");J41BN :]?X')?-9EVGS,:!57_?8^G9OU(BP+@;.[#*;6B7D61(%=A=B<
M@DN>_8C[^/-.4EJ7?8,52)A5G:ZS:F G^!>1O"P2 R($=P:,*'U6G(X1(]1
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MV1!2YP%YK[%331T)8,^Y39/R16=C;L_U8'&HI1(!8$;W1J8HD)9I4XP9G[W
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M"WO#X;#(L_D.R::+0+KR-8"]3V0M8/6>&K($3#I@_V;[J'T8QXC= "\#RSK
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MR;1I(P3U%&2"W(DYDG"B T8,%2.8 5V)3@\E@3+'=7,M/X-Q59OE0UQ0B!&
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MB&YD-$9VX<'4 BOCZ<SFVRZPQY;GS":08B7(3%,VG0O+^(<(W!'[._!*&:A
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MC[D!77=7Y)&[[QZ#VUUXWQM\L?TP5\5UMKC^O<CORQNSB[AEB\<I80)C' L
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MJ;VIB(A4A1@SU?LNHITJ(R.X?A!8[>#+PK<U-NKD"**O^V$H]C;NCV.;L>%
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MZ; '8QZIZQ?]"4\A7P[>:%%_LW@"WAD>.-J[_Z%]:?\Z<;3W)U!+ 0(4 Q0
M   ( %V!>5M+**&TE \  )UO   1              "  0    !A<G=R+3(P
M,C4Q,3(U+FAT;5!+ 0(4 Q0    ( %V!>5ME0(^$9 (  !0'   1
M      "  <,/  !A<G=R+3(P,C4Q,3(U+GAS9%!+ 0(4 Q0    ( %V!>5LS
M&/IP_",   @] 0 8              "  582  !A<G=R+3(P,C4Q,3(U.&ME
M>#DY,2YH=&U02P$"% ,4    " !=@7E;[ZV=[T *   46   %0
M    @ &(-@  87)W<BTR,#(U,3$R-5]L86(N>&UL4$L! A0#%     @ 78%Y
M6XQ7HCO<!@  "C,  !4              ( !^T   &%R=W(M,C R-3$Q,C5?
=<')E+GAM;%!+!08     !0 % $H!   *2      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>arwr-20251125_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arwr-20251125.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000879407</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Arrowhead Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38042</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">304-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
